

B1 cont  
(c) the antibody dissociates a CD11b/CD18 complex.

B2  
15. (Twice Amended) An article of manufacture, comprising:

a container;

a label on said container; and

a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates that the composition can be used for treating stroke and the active agent in said composition is an anti-CD18 antibody, wherein at least one of the following conditions is present:

(a) the antibody binds to an extracellular domain of CD18 and inhibits or reduces CD18 biological activity,

(b) the antibody binds CD18 with an affinity of 4 nm or less, or

(c) the antibody dissociates a CD11b/CD18 complex.

B3  
17. (Twice Amended) A kit, comprising:

a first container, a label on said container, and a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates that the composition can be used for treating stroke, and the active agent in said composition is an anti-CD18 antibody;

a second container comprising a pharmaceutically-acceptable buffer; and instructions for using the anti-CD18 antibody to increase cerebral blood flow or reduce infarct size in focal ischemic stroke, wherein at least one of the following conditions is present:

(a) the antibody binds to an extracellular domain of CD18 and inhibits or reduces CD18 biological activity,

(b) the antibody binds CD18 with an affinity of 4 nm or less, or

(c) the antibody dissociates a CD11b/CD18 complex.

Please add the following new claims:

43

- 13  
--18. The method of Claim 1, wherein the anti-CD18 antibody binds to an extracellular domain of CD18 and inhibits or reduces ~~CD18 biological activity~~.
- 14  
18. The method of Claim 1, wherein the anti-CD18 antibody binds CD18 with an affinity of 4 nm or less.
- 15  
20. The method of Claim 1, wherein the anti-CD18 antibody binds CD18 with an affinity of 3 nm or less.
- 16  
21. The method of Claim 1, wherein the anti- CD18 antibody binds CD18 with an affinity of 1 nm or less.
- 17  
22. The method of Claim 1, wherein the anti- CD18 antibody dissociates the CD11b/CD18 complex.
- 18  
23. The method of Claim 1, wherein the anti-CD18 antibody binds to the epitope bound by H52 antibody. --

#### REMARKS

Claims 1-12 and 15-23 are now pending in this application.

Claim 1 has been amended to include the antibodies identified as being enabled by the Examiner in paragraph 8 of the outstanding official action. Support for the amendments to Claim 1 and similar amendments to Claims 16 and 17 is found in the specification as filed on page 8, lines 6-7 and lines 15-25. Support for new Claims 18-22 is found in the same locations. No new matter is believed to have been introduced.

#### REQUEST FOR RECONSIDERATION

Applicants' representative wishes to thank Examiners Gamble and Hill for the helpful and courteous discussion regarding the merits of this application on July 23, 1998. The substance of this discussion is set forth in more detail below.

#### Formal Matters

During the discussion noted above, Applicants' representative provided the Examiner with a copy of the Petition to convert priority application USSN 08/589,982 to a provisional application. This Petition has now been decided and granted. A copy of the Decision on the Petition and official Filing Receipt for the provisional application are

44